icon-folder.gif   Conference Reports for NATAP  
 
  37th Annual Meeting of the European Association for the Study of the Liver
 
Madrid, Spain, April, 2002
Back grey_arrow_rt.gif
 
 
 
Bone Mineral Density Loss in HCV
 
Reported by Jules Levin
 
  DECREASED BONE MINERAL DENSITY IN NONCIRRHOTIC PATIENTS WITH CHRONIC HEPATITIS B OR C
 
Ingolf Schiefke 1 , Gudrun Borte 2 , Manfred Wiese 3 , Eva Schenker 1 , A. Fach 1 Department of Gastroenterology, University of Leipzig; 2 Department of Radiology, University of Leipzig; 3 Muncipal Hospital `St. Georg', Teaching Hospital of the University of Leipzig, Germany
 
Background/Aims: Several previous studies suggest that loss of bone mineral density is common among patients with chronic liver diseases. We studied bone mineral metabolism and density in patients with chronic hepatitis B or C without cirrhosis.
 
Methods: Biochemical markers of bone turnover and bone mineral density were measured in 42 consecutive patients. They are suffering from viral hepatitis B (n = 13) and hepatitis C (n = 29). Bone mineral density was measured by dual x-ray absorptiometry in the lumbar spine and femoral neck. The values were expressed as the T and Z score. Bone metabolism markers and hormone profiles were measured.
 
Results: Bone mineral density was lowered in 29 (69%) of our investigated 42 patients with chronic hepatitis B or C (femoral neck: 0.711 0.129 g/cm*cm; lumbar spine: 0.951 0.126 g/cm*cm). 8 of the 29 osteopenic patients (28%) have osteoporosis. T-score value in chronic Hepatitis C patients was more decreased (femoral neck T: ·1.59 0.98; lumbar spine T: ·1.10 1.09) compared with patients with chronic hepatitis B (femoral neck T: ·1.31 1.00; lumbar spine T: ·0.79 1.29). Serum and urine biochemical markers were within the normal limits in both groups.
 
Conclusion: Chronic hepatitis B or C in noncirrhotic patients may induce bone loss. In view of our results and according to previous studies this secondary effect of chronic hepatitis should be further investigated in following studies with larger number of included patients. Markers of bonemetabolism and bone mineral density might be used in monitoring these patients to reduced their risk of developing osteoporosis.